Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-24T15:39:32.708Z Has data issue: false hasContentIssue false
  • English
  • Français

111 A Novel Dual-Channel Deep Transcranial Magnetic Stimulator for Major Depressive Disorder

Published online by Cambridge University Press:  15 June 2018

Eiran V Harel ,
Dikla Shmuel ,
Daniel Antler ,
Dana Katz ,
Elina Pushkarski ,
Ezekiel Ais ,
Anna Schvartz ,
Aron Tendler ,
Yiftach Roth  and
Abraham Zangen
...Show all authors
Eiran V Harel
Affiliation:
Beer Yaakov Nes Ziona Mental Health Center, Beer Yaakov, Israel
Dikla Shmuel
Affiliation:
Beer Yaakov Nes Ziona Mental Health Center, Beer Yaakov, Israel
Daniel Antler
Affiliation:
Beer Yaakov Nes Ziona Mental Health Center, Beer Yaakov, Israel
Dana Katz
Affiliation:
Beer Yaakov Nes Ziona Mental Health Center, Beer Yaakov, Israel
Elina Pushkarski
Affiliation:
Beer Yaakov Nes Ziona Mental Health Center, Beer Yaakov, Israel
Ezekiel Ais
Affiliation:
Beer Yaakov Nes Ziona Mental Health Center, Beer Yaakov, Israel
Anna Schvartz
Affiliation:
Beer Yaakov Nes Ziona Mental Health Center, Beer Yaakov, Israel
Aron Tendler
Affiliation:
Chief Medical Officer, Brainsway, Jerusalem, Israel
Yiftach Roth
Affiliation:
Chief Scientist, Brainsway, Jerusalem, Israel
Abraham Zangen
Affiliation:
Professor, Ben Gurion University, Beer Sheva, Israel
Yechiel Levkovitz
Affiliation:
Beer Yaakov Nes Ziona Mental Health Center, Beer Yaakov, Israel
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Repetitive deep transcranial magnetic stimulation (dTMS) is efficacious for treatment resistant major depressive disorder (TRD) with the H1 coil by stimulating the prefrontal cortex, left more than right, at high frequency. Theoretically, the efficacy of dTMS could be optimized by simultaneously stimulating the right and left lateral prefrontal cortices (PFC) with different frequencies. This study tested the efficacy of a novel dual-channel dTMS stimulator with dual dTMS coils, in patients with TRD.

Methods

This study recruited forty-seven outpatients diagnosed with TRD, age 18-65, Hamilton Depression Rating Scale (HDRS-21) score ≥25. Each patient received 20 open label treatment sessions, five days a week for 4 consecutive weeks. Treatments were administered with the dual-channel stimulator (Brainsway Multiway dTMS device) using two channels: a. 10 Hz over the left PFC. b. 1 Hz over the right PFC. Primary and secondary efficacy outcome measures were the change in HDRS-21 score and response/remission rates at week 5, respectively.

Results

The HDRS-21 score decreased from an average of 25.94 to 14.69 (P<0.001). Thirty-six patients completed four weeks of treatment. Of them, seventeen (47%) responded (HDRS-21 score decrease of ≥ 50% from their initial score) and eight (22%) remitted (HDRS-21 score of < 10 at the end of the study).

Discussion

This open study shows promising results for multichannel simultaneous dTMS treatment of TRD using the Brainsway Multiway Device. Further randomized controlled studies are necessary to aid the high number of patients with TRD.

Funding Acknowledgements

Brainsway Ltd.

Type
Abstracts
Information
CNS Spectrums , Volume 23 , Issue 1 , February 2018 , pp. 71 - 72
Copyright
© Cambridge University Press 2018